

About OncoBeta

OncoBeta is an international MedTech company focused on innovative skin-directed therapies for non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The company specializes in the development and commercialization of Rhenium-SCT®, a personalized epidermal radionuclide therapy utilizing the beta-emitter Rhenium-188.

Headquartered in Garching bei München, OncoBeta operates internationally across medical, scientific, clinical, and commercial environments, collaborating with healthcare professionals, treatment centers, and research institutions to improve outcomes in non-melanoma skin cancer care.

The company's core focus is advancing non-invasive, skin-directed radionuclide therapies designed to support effective treatment while preserving function, aesthetics, and patient quality of life. Rhenium-SCT® is designed as a single-session, personalized treatment approach that applies beta radiation directly to superficial skin lesions while minimizing exposure to surrounding healthy tissue.

OncoBeta is also actively involved in clinical research and real-world evidence generation through international initiatives such as the EPIC-Skin Study and the OncoBeta International Registry. These programs evaluate treatment efficacy, patient-reported outcomes, treatment comfort, cosmetic outcomes, and long-term quality-of-life data across multiple international centers.

OncoBeta also develops and supplies Tungsten-188/Rhenium-188 generators and related application systems to support the production and delivery of therapeutic radionuclides in clinical environments.

As a pioneer and innovator in the field of epidermal radioisotope therapies, OncoBeta is committed to developing and delivering therapies that fulfill their clinical promise while contributing to one clear mission: improving patients' quality of life.